GLI1 and non-small cell lung carcinoma: Additionally, as EMT affects the sensitivity of NSCLC cell lines to common therapeutic agents including erlotinib, cisplatin and paclitaxel (38–40), targeting Gli1 may improve the efficacy of these therapies.